susceptibility or lack thereof to the most effective anti-TB medications that exist. Multi-drug resistant TB (MDR-TB) is the title given to infection with organisms that are already resistant to or become resistant during treatment to isoniazid and rifampin, the first line drugs in the treatment of this disease. More concerning, however, is extensively drug resistant TB (XDR-TB). These strains have acquired mechanisms to prevent susceptibility to not only isoniazid and rifampin but also to fluoroquniolones and amikacin, kanamycin and capreomycin, the second-line injectable TB medications. If responsive to the drugs at all, the treatment course is usually 2 years in duration. 9 This is concerning as XDR-TB has now been described in 84 countries with as many as 9% of all MRD-TB cases being extensively drug resistant. 10 The alarming fact is that XDR-TB is associated with a higher probability of death and decreased treatment success when compared to MDR-TB. 11 Reason for this resistance pattern is thought to be multifactorial: incorrect drug or dose choice, abbreviated treatment duration, poor-adherence to the regimen, or in many low income countries, lack of access to medication and supplies. 12 A study recently performed in India, looked at the association between XDR-TB and various comorbidities. Researchers found that those with other medical maladies, such as diabetes, myasthenia gravis and thalassemias, had a higher tendency toward resistance. It was concluded that this was likely secondary to poor immune response leading to extended disease chronicity, and therefore, more of an opportunity for mutations to develop. Moreover, they looked at the socioeconomic status of those with XDR-TB and found that poor living conditions and poor nutrition as well as lack of access to health care put individuals at higher risk for developing resistance. Finally, they found that 94.4% of individuals with XDR-TB had previously been treated for TB, although the details of their treatment regimens could not be devised. 13 One mechanism thought to decrease the likelihood of resistance is to identify and diagnose tuberculosis early and to continue treatment without interruption. In order to accomplish these goals, directly observed therapy [or DOT] was implemented. By assigning specific individuals to watch patients take their medications, the thought is that compliance with and completion of prescribed course of anti-TB drugs leads to a cure of their infection thereby not only preventing spread of the disease to others but also lessening the chance of drug resistance within the community. Despite the findings of a Cochrane review performed in 2007, which concluded that there was no significance in outcomes between DOT and self-administration of anti-TB drugs, DOT is frequently implemented in the treatment of high-risk patients. 14 XDR-TB has been found not only in developing nations but also in the first world. An article published in Emerging Health Threats in 2012 flagged XDR-TB as one of the top 5 infections thought to present an overall threat to global public health with the reason being that in the setting of resistant strains, widespread transmission of the disease count be catastrophic. 15 Whereas extremely resistant strains of Mycoplasma tuberculosis already exist, the concern has now arisen that completely resistant strains will present next. For this reason, it is imperative not only to preserve the efficacy of first and second-line TB treatments but to also investigate new TB drugs and encourage pharmaceutical companies to work toward development of such compounds. It has been more than 40 years since a new anti-TB drug was introduced into clinical practice. Currently, there are multiple novel drugs in the early stages of discovery of which one has now reached Phase II clinical investigation.
In the modern age of global travel, tuberculosis is no longer confined to strictly endemic areas; rather, it can present anywhere. For this reason, in those suspected of infection, it is imperative that the proper prevention techniques, such negative pressure isolation rooms when in the hospital and N95 masks be worn. Furthermore, it is imperative that those infected with this organism complete the full treatment course as increased prevalence of XDR-TB could clearly lead to a world-wide epidemic.
